Chimerix Inc. Stock
Chimerix Inc. Stock
With 3 Buy predictions and 2 Sell predictions the community is currently undecided on Chimerix Inc..
With a target price of 10 € there is a positive potential of 32.98% for Chimerix Inc. compared to the current price of 7.52 €.
Our community identified positive and negative aspects for Chimerix Inc. stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Chimerix Inc. stock. On the other hand our users think that "Innovation" could be a problem in the future.
Pros and Cons of Chimerix Inc. in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Chimerix Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Chimerix Inc. | - | - | - | - | - | - | - |
| Ardelyx Inc. | 5.570% | 2.840% | 1.187% | 5.509% | 6.465% | 176.349% | -3.856% |
| Krystal Biotech | 0.330% | 3.678% | 18.962% | 25.776% | 37.057% | 193.803% | - |
| Evolus Inc | -4.200% | -1.724% | -8.065% | -47.706% | -45.714% | -18.571% | 88.742% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2025-04-26
CHIMERIX INC (CMRX) is currently in a challenging financial position, characterized by significant losses and declining revenue. Key findings include:
The overall financial trend is negative due to declining revenue and persistent significant losses.
In conclusion, while CHIMERIX INC maintains a strong liquidity position and continues to invest in R&D, the significant decline in revenue and persistent substantial losses are major concerns. The company's financial health is currently challenged, and its ability to achieve profitability and growth will be critical for its long-term success.
Comments
Chimerix, Inc. (NASDAQ: CMRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for CMRX provided by MarketBeat
Chimerix, Inc. (NASDAQ: CMRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for CMRX provided by MarketBeat
Chimerix, Inc. (NASDAQ: CMRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Show more
Ratings data for CMRX provided by MarketBeat